CNBC · Aug 27, 2026
FDA approves Gilead's daily HIV pill
CNBC's Annika Kim Constantino reports on the FDA's decision to approve Gilead's daily HIV pill.
NASDAQ · GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$145.68
Down-$3.18 (-2.14%)
Updated Aug 31, 2026, 7:06 AM
SID Score
7.4/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 152.89B
- P/E ratio
- 18.89
- Dividend yield
- 2.70%
- 52-week range
- $116.88 – $157.29
- Volume
- 3.95M
- Avg. volume
- 7.34M
Price performance
GILD price history
1M range · 20 trading sessions · Daily adjusted prices
GILD closed at $145.68 after 20 trading sessions, up 11.08% for the selected period.
- Last close
- $145.68
- Period change
- +11.08%
- Period low
- $130.86
- Period high
- $148.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $149.47 | $149.47 | $144.88 | $145.68 | 3.95M |
| Aug 27, 2026 | $147.30 | $149.105 | $146.01 | $148.86 | 5.01M |
| Aug 26, 2026 | $148.00 | $149.6199 | $147.004 | $148.09 | 5.26M |
| Aug 25, 2026 | $146.60 | $148.94 | $145.58 | $148.77 | 4.63M |
| Aug 24, 2026 | $145.93 | $146.835 | $144.59 | $146.74 | 6.18M |
| Aug 21, 2026 | $144.52 | $147.905 | $143.50 | $146.12 | 5.38M |
| Aug 20, 2026 | $146.69 | $146.82 | $143.19 | $143.44 | 7.17M |
| Aug 19, 2026 | $145.10 | $148.97 | $144.30 | $147.60 | 6.74M |
| Aug 18, 2026 | $140.00 | $143.89 | $139.54 | $143.44 | 5.76M |
| Aug 17, 2026 | $138.36 | $139.49 | $136.63 | $138.92 | 3.94M |
| Aug 14, 2026 | $136.81 | $138.4325 | $135.91 | $138.36 | 3.41M |
| Aug 13, 2026 | $136.94 | $138.30 | $136.03 | $138.14 | 4.9M |
| Aug 12, 2026 | $133.99 | $137.12 | $133.295 | $135.87 | 5.68M |
| Aug 11, 2026 | $132.68 | $136.85 | $132.01 | $135.77 | 5.49M |
| Aug 10, 2026 | $131.61 | $134.32 | $131.61 | $133.06 | 6.83M |
| Aug 7, 2026 | $132.10 | $134.09 | $130.59 | $133.21 | 8.2M |
| Aug 6, 2026 | $133.99 | $134.48 | $129.02 | $130.86 | 9.24M |
| Aug 5, 2026 | $136.00 | $137.80 | $129.60 | $131.76 | 11.38M |
| Aug 4, 2026 | $131.15 | $135.57 | $129.54 | $135.25 | 10.09M |
| Aug 3, 2026 | $131.095 | $131.50 | $129.04 | $131.15 | 7.52M |
Latest GILD news
The latest Smart Investors Daily articles mentioning GILD.
Stock researchCompany · Overview
GILD research
Overview
Company profile and research snapshot.
Company profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $130.64
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | RBC Capital | Sector Perform | — |
| Aug 5, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 5, 2026 | Needham | Buy | — |
| Jul 29, 2026 | Barclays | Equal-Weight | — |
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the
CNBC · Aug 27, 2026
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Benzinga · Aug 24, 2026
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market capitalization of
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
